InnFocus said Wednesday that results from a 3-year trial of its MicroShunt drainage system designed to treat glaucoma patients reported a significant reduction in intraocular pressure and the use of glaucoma medication. Results from the study were published in the Journal of Glaucoma, the company said. “These results show not only the potential effectiveness but […]
Optical/Ophthalmic
Novartis taps Hospira-sale engineer exec Ball to revive slumping Alcon
Novartis (NYSE:NVS) is looking to revitalize its slumping Alcon eye care division by picking up medical vet Michael Ball, who recently organized Hospira’s $15 billion sale to Pfizer (NYSE:PFE). Ball will replace previous Alcon chief Jeff George, the company announced today. Novartis CEO Joe Jimenez is reportedly putting Ball in control of reviving Alcon. Alcon […]
Glaukos touts 3-year iStent study data
Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery. The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared […]
Delcath launches Phase III trial for ocular melanoma treatment
Delcath (NSDQ:DCTH) said today it launched a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride designed for the treatment of hepatic dominant ocular melanoma. The newly initiated Focus trial will examine the safety, efficacy and pharmocokinetic profile of its Melphalan and HDS system when compared with the standard of care, the New […]
Delcath inks FDA deal for design of Phase III trial
Delcath (NSDQ:DCTH) said yesterday the company reached a special protocol assessment agreement with the FDA for the design of a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride. The system is designed to treat patients with hepatic dominant ocular melanoma, the New York City-based company said. The company said the agreement acted as a […]
Eye Tech Care lands $27m from Chinese investor
French glaucoma treatment developer Eye Tech Care SA said today it secured $27.2 million (EU €25 million) in funding from Chinese investor Everpine Capital. The money will come from Everpine in 2 rounds to support Eye Tech Care’s international expansion, the company said. “We are delighted to welcome Everpine as a financial and strategic shareholder. […]
CooperVision, EP Global go their separate ways in contact lens deal
EP Global Communications (OTC:EPGL) said it’s parting ways with Cooper Cos. (NYSE:COO) subsidiary CooperVision on a co-development project for advanced contact lens technology. Irvine, Calif.-based EP Global, which last year threw the gauntlet before Google (NSDQ:GOOG) on its much-ballyhooed smart contact lens program, said the Dec. 31 settlement with CooperVision allows each company to pursue the technology on its […]
FDA clears Glaukos Phase II iDose drug-eluting eye implant trial
Glaukos (NYSE:GKOS) said today it won a nod from the FDA for an investigational new drug Phase II study of its Travoprost intraocular implant utilizing the company’s iDose delivery system for patients with glaucoma. The iDose system is injected through a clear corneal incision and secured in the anterior chamber to continuously elute therapeutic levels of […]
Stealthy Clerio Vision raises $3.2m
Stealthy opthalmalogical surgery company Clerio Vision raised $3.2 million in a new round of equity financing to support its novel surgical treatment for individuals with refractive error. The Rochester, N.Y.-based company is developing a surgical strategy using a femtosecond laser to change the refractive index of the cornea with small pulses to noninvasively correct the […]
eyeBrain Medical pulls in $6m for NeuroLens chronic headache treatment
Hybrid neurological and ophthalmological company eyeBrain Medical raised $6 million in a new round of equity financing for its chronic severe headache treatment technology. The company is aiming to treat what it calls ‘eyegraines’, or visual misalignments between images from both eyes that eyeBrain says can over stimulate the trigeminal nerve in the brain and […]
pSivida surges on Medidur data
Psivida (NSDQ:PSDV) shares surged today after the company said its Medidur drug-device combination met the primary endpoints in a Phase III clinical trial for treating posterior uveitis. Medidur uses the same injectable implant and drug as the Iluvien drug-device combo pSivida licensed to Alimera Sciences (NSDQ:ALIM) for treating diabetic macular degeneration. Iluvien won FDA approval in September […]